Author:
Mengoli Carlo,Andreis Samantha,Scaggiante Renzo,Cruciani Mario,Bosco Oliviero,Ferretto Roberto,Leoni Davide,Maffongelli Gaetano,Basso Monica,Torti Carlo,Sarmati Loredana,Andreoni Massimo,Palù Giorgio,Parisi Saverio Giuseppe
Funder
Ministero dell'Università e della Ricerca Scientifico-Tecnologica
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)
Reference36 articles.
1. Backbones versus core agents in initial ART regimens: one game, two players
2. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1
3. Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
4. Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study
5. Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy?;Wood;J Acquir Immune Defic Syndr,2005